Evidence map›Paper›PMID 40707718›Full record

ArticleNPJ precision oncology2025

LINE1 insertion into the NACC2 locus disrupts the HDM2 axis and activates lung oncogenic signaling.

Pasano Bojang, Yingshan Wang, Kenneth S Ramos

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pasano Bojang *Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA.
Yingshan Wang *Center for Genomic and Precision Medicine, Institute of Biosciences and Technology Texas A&M Health Science Center, Houston, TX, USA.
Kenneth S RamosDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA. kramos@tamu.edu.

Funding

Functional Genomics of LINE-1 RetrotranspositionR01ES034542 · NIEHS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Kenneth S. Ramos · 2022 to 2026
$3.2M
Cancer Prevention and Research Institute of Texas RP230204NIEHS NIH HHS R01 ES034542NIEHS NIH HHS R01ES034542State of Texas GURI AWARD 01-2019
6 · The paper itself

Abstract

Although long interspersed element-1 (LINE-1) retrotransposons are poor prognostic indicators of non-small cell lung cancer, the genetic consequences of aberrant LINE-1 expression remain poorly understood. In this study, human bronchial epithelial cells were exposed chronically to 25 µM NiCl₂ to induce malignant transformation and compared to PBS-treated control cells or lung cancer cell lines. A 4 kb intronic LINE-1 insertion into the NACC2 (nucleus accumbens-associated protein 2) locus in nickel-transformed cells was associated with significant reductions in NACC2 mRNA and protein, along with constitutive increases in HDM2 and TP53α mRNAs, and aberrant expression of TP53β and TP53γ mRNAs. Steady-state levels of p53 and RB decreased, while EGFR and LINE-1 ORF1p increased. Silencing of NACC2 in TP53 wildtype NCI-H460 or TP53-null NCI-1299 cell lines replicated many of these changes, with profiles varying as a function of p53 status. Stable overexpression of HDM2 increased LINE-1 ORF1p in cancer cell lines. Human lung adenocarcinomas with wild-type TP53 showed sexually dimorphic profiles, with higher HDM2 levels in females than males, and shifts in LINE-1 ORF1p, p53, and RB that mirrored cancer cell lines. This study identifies the NACC2 locus as a target of LINE-1 retrotransposition and highlights critical interactions with the HDM2/TP53/RB regulatory axis.

Identifiers

PMID40707718
PMCPMC12289886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.